Tailored timing of radioactive therapy may boost tumor control in NETs

NCT ID NCT05387603

Recruiting now Disease control Sponsor: Lund University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether personalizing the schedule of a radioactive drug (177Lu-DOTATOC) improves outcomes for people with advanced neuroendocrine tumors. About 300 participants will receive either a standard or personalized treatment plan, with some also taking capecitabine. The goal is to see if tailoring therapy extends the time before tumors grow again.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-DOTATOC (a radioactive drug) and capecitabine (a chemotherapy pill)
What this could lead to: If successful, this could show that personalizing the timing of radioactive therapy improves how long tumors stay controlled, with fewer side effects.
What could go wrong: This is a large phase 3 trial, but personalization may not significantly improve outcomes over standard care. Radioactive therapy carries risks like kidney damage and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Accademical Hospital, Uppsala, Dept. of Oncology
RECRUITING

Uppsala, SE-752 37, Sweden
Karolinska University Hospital, Dept. of Oncology
RECRUITING

Stockholm, SE-171 76, Sweden
Sahlgrenska University Hospital, Dept. of Oncology
RECRUITING

Gothenburg, Sweden
Skåne University Hospital, Dept. of Oncology
RECRUITING

Lund, SE-226 52, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.